Resverlogix Scientific Data Presented at EAS Congress

Hamburg and Calgary, Canada, June 22, 2010 (ots/PRNewswire) -
Resverlogix Corp. ("Resverlogix" or the "Company") announced today
that key scientific data was communicated in an oral presentation
highlighting the novel features of the Company's lead drug RVX-208 at
the European Atherosclerosis Society Congress (EAS) conference being
held in Hamburg, Germany. The presentation titled "RVX-208 given
orally raises plasma ApoA-I and HDL in human clinical trials," was
presented by Dr. Norman Wong, MD, Chief Scientific Officer of
Resverlogix.

"The data presented in Germany today further highlights that
patients with low HDL/Apo-Al benefit most. For those patients in the
highest risk category, subjects with low baseline HDL/Apo-Al, our
data demonstrated that RVX-208 increased plasma levels of Apo-Al in
the order of 13.25% compared to placebo. This data, combined with
similar low baseline HDL/Apo A-l data analysis of the upcoming ASSERT
trial data will further support the design of a very effective and
efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of
Resverlogix.

Resverlogix recently completed a Phase 2 clinical trial called
ASSERT to study RVX-208 an oral small molecule therapy for the
treatment of atherosclerosis. The ASSERT trial enrolled subjects with
stable coronary artery disease. A second planned Phase 2 trial,
designated ASSURE, will include subjects with acute coronary syndrome
and coronary artery disease of whom all will be examined with
intravascular ultrasound (IVUS). Both the ASSERT and ASSURE studies
are chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland
Clinic Department of Cardiovascular Medicine and the principal
investigator is Dr. Stephen Nicholls, Medical Director of
Intravascular Ultrasound at the Cleveland Clinic.

Cardiovascular disease is the leading cause of death in the US
and other developed nations costing the American health care system
an estimated USD$448.5 billion in 2008. According to the American
Heart Association's Heart Disease & Stroke Statistics 2010
publication, approximately every 25 seconds an American will have a
coronary event and approximately every minute, someone will die from
such an event. A key underlying cause of cardiovascular disease is
atherosclerosis, a build-up of plaque in the arteries often referred
to as 'hardening of the arteries'.

Apolipoprotein A-I (ApoA-I), the main protein component of
high-density lipoprotein (HDL), represents the body's natural defense
system against atherosclerosis by mediating reverse cholesterol
transport, i.e. transport of peripheral cholesterol including that
within the atherosclerotic plaques of the vessel wall to the liver
for processing and excretion. In multiple human and animal studies
over-expression or repeated infusion of ApoA-I inhibit progression
and induce regression of atherosclerosis in animals and humans.
Developing small molecules that increase ApoA-I would satisfy a large
unmet medical need.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet medical needs. The NexVas(TM) PR
program is the Company's primary focus which is to develop novel
small molecules that enhance ApoA-I. These vital therapies address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral
Artery Disease and other vascular disorders. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange . For further
information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements
as defined under applicable Canadian securities legislation,
including our statements with respect to, the current and/or future
financings, research, development and commercialization of novel
therapeutics that reduce the risk of cardiovascular disease including
atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery
Disease and other vascular diseases. These forward-looking statements
contained herein that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous known and unknown
risks and uncertainties including but not limited to those associated
with the success of research and development programs, clinical trial
programs including possible delays in patient recruitment, the
regulatory approval process, competition, securing and maintaining
corporate alliances, market acceptance of the Company's products, the
availability of government and insurance reimbursements for the
Company's products, the strength of intellectual property, financing
capability, the potential dilutive effects of any financing, reliance
on subcontractors and key personnel and additional risk factors
discussed in other documents we file from time to time with
securities authorities, which are available through SEDAR at
http://www.sedar.com. Additionally, risks and uncertainties are
discussed in detail in the January 31, 2010 MD&A. The
forward-looking statements contained in this news release are
expressly qualified by this cautionary statement are made as of the
date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. The TSX Exchange does not
accept responsibility for the adequacy or accuracy of this news
release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-403-254-9252 ext. 300,
Fax: +1-403-256-8495, Email:Theresa@resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Theresa Kennedy, VP,
CorporateCommunications,Resverlogix Corp., Phone: +1-403-254-9252
ext. 300, Fax: +1-403-256-8495,Email:Theresa@resverlogix.com